On November 17, 2016, the Judge handling the Taxotere (Docetaxel) Products Liability Litigation (MDL 2740) issued Pretrial Order No. 2 appointing counsel as Plaintiffs’ Liaison Counsel, Defendants’ Liaison Counsel and to the Plaintiffs’ Steering Committee. All appointments are for a 1 year term beginning immediately until January 1, 2018. Applications for the subsequent term must be...
On October 3, 2016, the U.S. District Court for the Eastern District of Louisiana consented to assignment of the actions alleging that the chemotherapy drug, Taxotere, can cause permanent hair loss, particularly in those being treated for breast cancer, to the Honorable Lance M. Africk for coordinated or consolidated pretrial proceedings. As previously reported in...
On July 22, a motion was filed requesting a new multidistrict litigation (MDL) for lawsuits alleging that Sanofi SA’s chemotherapy drug, Taxotere, can cause permanent hair loss, particularly in those being treated for breast cancer. Multidistrict litigation is a special procedure in which federal civil (noncriminal) cases from around the country are transferred to one...
Temporary hair loss following chemotherapy is hard enough. Unfortunately, as acknowledged by the FDA, cases of permanent hair loss (alopecia) have been reported in patients who have been given the chemotherapy drug, Taxotere®. Now a breast cancer survivor from Ohio, Hattie Carson, has decided to take on Sanofi-Aventis in Ohio Federal Court. According to her complaint, Ms. Carson underwent...
Copyright ©2024 Borgess Law
Law Firm Web Design by Black Fin